DEF: Denali Therapeutics Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals

Denali Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 3, 2025, to vote on director elections, auditor ratification, and executive compensation.

Summary

• Denali Therapeutics Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 3, 2025, at 10:00 a.m. Pacific Time.
• Stockholders of record as of April 9, 2025, are entitled to vote.
• The meeting will address the election of three directors, ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and an advisory vote on executive compensation.
• The Board recommends voting FOR the election of the director nominees, FOR the ratification of Ernst & Young LLP, and FOR the approval of executive compensation.
• As of the record date, April 9, 2025, there were 145,242,212 shares of common stock outstanding and entitled to vote.
• The company's board of directors is currently composed of 10 members, which will be reduced to 9 members effective on the date of the Annual Meeting.
• Julian C. Baker, Peter Klein, and Steve E. Krognes are nominated for election as Class II directors.
• Vicki Sato, Ph.D. and Erik Harris are departing from the board of directors following the Annual Meeting.
• The company's non-employee directors are subject to stock ownership guidelines to promote the ongoing alignment of the interests of our directors with the long-term interests of our stockholders.
• The company's CEO Pay Ratio for 2024 is approximately 19:1.
• Stockholders may submit proposals for the 2026 annual meeting, with deadlines specified in the proxy statement.

Sentiment

Score: 7

Explanation: The document is neutral in tone, providing factual information about the upcoming annual meeting and related proposals. The company's performance and compensation practices are presented without significant positive or negative spin.

Positives

• The Board recommends voting FOR all proposals, indicating confidence in the company's direction.
• The company has established corporate governance guidelines and a code of business conduct and ethics.
• The company has adopted a Compensation Recovery Policy, which applies to all covered employees to reflect and comply with these new requirements.
• The company has a formal written policy providing that our audit committee will be responsible for reviewing related party transactions.

Negatives

• The company's board of directors is currently composed of 10 members, which will be reduced to 9 members effective on the date of the Annual Meeting.
• Vicki Sato, Ph.D. and Erik Harris are departing from the board of directors following the Annual Meeting.

Risks

• The classification of the board of directors may have the effect of delaying or preventing changes in control of the company.
• The company's success depends on attracting and retaining key personnel.
• The company's business is subject to various risks, including financial, accounting, disclosure and corporate compliance, information security and cybersecurity risks.
• The company's business is subject to compliance with legal and regulatory requirements.

Future Outlook

The company is preparing for a potential commercial launch of tividenofusp alfa in late 2025 or early 2026.

Management Comments

• Ryan J. Watts, Ph.D., President and Chief Executive Officer, expresses appreciation for stockholders' interest in Denali.
• The board of directors believes that separation of the positions of Chairperson and Chief Executive Officer reinforces the independence of the board of directors from management.

Industry Context

Denali Therapeutics operates in the biotechnology industry, focusing on discovering, developing, and delivering therapies for neurodegenerative and lysosomal storage diseases. The company's peers include other late-stage, pre-commercial, and early commercial biopharmaceutical companies with a similar therapeutic focus.

Comparison to Industry Standards

• The company benchmarks its executive compensation against a peer group of companies including Agios Pharmaceuticals, CRISPR Therapeutics, Prothena Corporation, Alector Therapeutics, Cytokinetics, REGENXBIO, Amylyx Pharmaceuticals, Intellia Therapeutics, Sage Therapeutics, Arcus Biosciences, Intra-Cellular Therapies, Sarepta Therapeutics, Axsome Therapeutics, Ionis Pharmaceuticals, Ultragenyx Pharmaceutical, Beam Therapeutics, Karuna Therapeutics, Vaxcyte, BridgeBio Pharma, Legend Biotech Corp., Vir Biotechnology, Cerevel Therapeutics Holdings and Mirati Therapeutics.
• The company's outside director compensation policy aims to provide reasonable compensation to non-employee directors that is commensurate with their contributions and appropriately aligned with its peers.
• The company's outside director compensation policy provides that until at least the date of the annual meeting held in 2025, neither the cash retainers nor the value of equity compensation payable under our outside director compensation policy will be raised to a level that is in excess of the 75th percentile of the cash retainers or value of equity award compensation, respectively, paid by the then-applicable peer group, as approved by the compensation committee of our board of directors, to their non-employee directors.

Management Changes

Corporate Governance

Related Party Transactions

• In February 2024, Denali entered into a securities purchase agreement with the Baker Funds, resulting in the purchase of shares and pre-funded warrants for approximately $444.0 million.
• In connection with the Purchase Agreement, Denali entered into a nominating agreement with the Baker Funds.
• In connection with the Purchase Agreement, Denali agreed to enter into a registration rights agreement with the Baker Funds.

Stakeholder Impact

• Shareholders are asked to vote on key proposals that will shape the company's governance and executive compensation.
• Employees are impacted by the company's compensation policies and practices.
• The company's corporate responsibility initiatives aim to positively impact the community and environment.

Next Steps

• Stockholders are encouraged to vote via the Internet, telephone, or mail as soon as possible.
• The company will file a current report on Form 8-K within four business days after the Annual Meeting to publish the final voting results.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Board of Directors, Executive Compensation, Director Election, Auditor Ratification, Corporate Governance, Denali Therapeutics, Stockholders